Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Feb 19, 2019 - Many dividend growth investors seek the highest-quality companies.Independent data providers such as S&P, Morningstar, and Simply Safe Dividends offer rankings of quality factors.A simple scoring syst
Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Feb 16, 2019 - Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi (NASDAQ:SNY) announce that the USPTO has invalidated 17 claims as obvious of U.S. Patent No. 8,679,487 owned by Amgen's (NASDAQ:A
Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Feb 13, 2019 - Amgen (AMGN) will collaborate with privately held Abilita Bio to discover new drugs that target complex membrane proteins by leveraging the latter's Enable Membrane Protein (EMP) platform.Acco
Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Feb 12, 2019 - AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.